Controversies in the use of drug-eluting stents for acute myocardial infarction: A critical appraisal of the data

Annual Review of Medicine

Volumn 61, Issue , 2010, Pages 215-231

  Sakhuja, Rahul ^a,b   Mauri, Laura ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Clinical trials; Coronary stent; Restenosis; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; PEXELIZUMAB; PRASUGREL; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BARE METAL STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; HUMAN; IN-STENT RESTENOSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SAFETY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; ADULT; GRAFT OCCLUSION; HEART INFARCTION; MORTALITY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 77951927591     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.051508.221014     Document Type: Review

References (91)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. 2009. Heart disease and stroke statistics\2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:480-486
2. Mauri L, Silbaugh TS, Garg P, et al. 2008. Drug-eluting or bare-metal stents for acute myocardial infarction. N. Engl. J. Med. 359:1330-1342
3. Keeley EC, Boura JA, Grines CL. 2003. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13-20
4. Boden WE, O'Rourke RA, Teo KK, et al. 2007. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356:1503-1516
5. Machecourt J, Danchin N, Lablanche JM. 2004. The national registry EVASTENT: cost-effectiveness analysis of the sirolimus active stent in diabetic and nondiabetic patients. Ann. Cardiol. Angeiol. (Paris) 53(Suppl. 1):22s-28s
6. Mehta SR, Cannon CP, Fox KA, et al. 2005. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293:2908-2917
7. Antoniucci D, Santoro GM, Bolognese L, et al. 1998. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J. Am. Coll. Cardiol. 31:1234-1239
8. Rodriguez A, Bernardi V, Fernandez M, et al. 1998. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am. J. Cardiol. 81:1286-1291
9. Saito S, Hosokawa G, Tanaka S, et al. 1999. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. Catheterization Cardiovasc. Interv. 48:262-268
10. Suryapranata H, Ottervanger JP, Nibbering E, et al. 2001. Long-term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart 85:667-671
11. Williams DO, HolubkovR,YehW,etal. 2000. Percutaneous coronary interventioninthe current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 102:2945-2951
12. Morice MC, Serruys PW, Sousa JE, et al. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:1773-1780
13. Moses JW, Leon MB, Popma JJ, et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:1315-1323
14. Schampaert E, Cohen EA, Schluter M, et al. 2004. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol. 43:1110-1115
15. Schofer J, Schluter M, Gershlick AH, et al. 2003. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093-1099
16. Stone GW, Ellis SG, Cox DA, et al. 2004. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350:221-231
17. Morice M-C, Serruys PW, Barragan P, et al. 2007. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J. Am. Coll. Cardiol. 50:1299-1304
18. Weisz G, Leon MB, Holmes DR Jr, et al. 2009. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J. Am. Coll. Cardiol. 53:1488-1497
19. Caixeta A, Leon MB, Lansky A, et al. 2009. 5-Year clinical outcomes after sirolimus-eluting stent implantation: insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J. Am. Coll. Cardiol. 54:894-902
20. FajadetJ,WijnsW,Laarman GJ,etal. 2006. Randomized, double-blind, multicenter studyofthe Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114:798-806
21. Serruys PW, Ong AT, Piek J, et al. 2005. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1:58-65
22. Tsuchiya Y, Lansky AJ, Costa RA, et al. 2006. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am. J. Cardiol. 98:464-469
23. Mauri L, Hsieh WH, Massaro JM, et al. 2007. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356:1020-1029
24. Stone GW, Moses JW, Ellis SG, et al. 2007. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356:998-1008
25. Daemen J, Wenaweser P, Tsuchida K, et al. 2007. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667-678
26. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. 2008. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J. Am. Coll. Cardiol. 51:986-990
27. Jensen LO, Maeng M, Kaltoft A, et al. 2007. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J. Am. Coll. Cardiol. 50:463-470
28. Park DW, Park SW, Park KH, et al. 2006. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98:352-356
29. Spaulding C, Henry P, Teiger E, et al. 2006. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N. Engl. J. Med. 355:1093-1104
30. Drachman DE, Edelman ER, Seifert P, et al. 2000. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36:2325-2332
31. Joner M, Finn AV, Farb A, et al. 2006. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48:193-202
32. Nakazawa G, Finn AV, Joner M, et al. 2008. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118:1138-1145
33. Fujii K, Carlier SG, Mintz GS, et al. 2005. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J. Am. Coll. Cardiol. 45:995-998
34. Uren NG, Schwarzacher SP, Metz JA, et al. 2002. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur. Heart J. 23:124-132
35. Cook S, Wenaweser P, Togni M, et al. 2007. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115:2426-2434
36. Sanchez-Recalde A, Moreno R, Barreales L, et al. 2008. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials. J. Invasive Cardiol. 20:417-422
37. Hoffmann R, Morice MC, Moses JW, et al. 2008. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart 94:322-328
38. Sianos G, Papafaklis MI, Daemen J, et al. 2007. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J. Am. Coll. Cardiol. 50:573-583
39. Hwang CW, Levin AD, Jonas M, et al. 2005. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 111:1619-1626
40. Nebeker JR, Virmani R, Bennett CL, et al. 2006. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 47:175-181
41. Virmani R, Guagliumi G, Farb A, et al. 2004. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 109:701-705
42. Lagerqvist B, James SK, Stenestrand U, et al. 2007. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356:1009-1019
43. James SK, Stenestrand U, Lindback J, et al. 2009. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N. Engl. J. Med. 360:1933-1945
44. Steg PG, Fox KA, Eagle KA, et al. 2009. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur. Heart J. 30:321-329
45. Austin D, Pell JP, Oldroyd KG. 2007. The rise and fall of drug-eluting stents: time trend analysis in 13647 consecutive patients undergoing percutaneous coronary intervention. Am. Heart J. 154:e37
46. Kukreja N, Onuma Y, Garcia-Garcia H, et al. 2008. Primary percutaneous coronary intervention for acute myocardial infarction. Circ. Cardiol. Interv. 1:103-110
47. Stone GW, Lansky AJ, Pocock SJ, et al. 2009. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N. Engl. J. Med. 360:1946-1959
48. Iakovou I, Schmidt T, Bonizzoni E, et al. 2005. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126-2130
49. Spertus JA, KettelkampR,VanceC,etal. 2006. Prevalence,predictors,and outcomesofpremature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113:2803-2809
50. Valgimigli M, Campo G, Percoco G, et al. 2008. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299:1788-1799
51. Diaz de la Llera LS, Ballesteros S, Nevado J, et al. 2007. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am. Heart J. 154:164e1-6
52. Kelbaek H, Thuesen L, Helqvist S, et al. 2008. Drug-eluting versus bare metal stents in patients with ST-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 118:1155-1162
53. Karjalainen PP, Ylitalo A, Niemela M, et al. 2008. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial. EuroIntervention 4:234-241
54. Van Der Hoeven BL, Liem SS, Jukema JW, et al. 2008. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J. Am. Coll. Cardiol. 51:618-626
55. Chechi T, Vittori G, Biondi Zoccai GG, et al. 2007. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J. Interv. Cardiol. 20:282-291
56. Menichelli M, Parma A, Pucci E, et al. 2007. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J. Am. Coll. Cardiol. 49:1924-1930
57. Laarman GJ, Suttorp MJ, Dirksen MT, et al. 2006. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N. Engl. J. Med. 355:1105-1113
58. Valgimigli M. 2007. 3 year follow-up after sirolimus-eluting vs BMS in AMI\clinical trial update 1. Eur. Soc. Cardiol. Congr. Rep. http://www.escardio. org/congresses/esc2007/reports/pages/1023-CTU1-Valgimigli.aspx. Accessed Mar. 15, 2009
59. Valgimigli M, Campo G, Arcozzi C, et al. 2007. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: results from the STRATEGY study. J. Am. Coll. Cardiol. 50:138-145
60. Valgimigli M, Percoco G, Malagutti P, et al. 2005. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293:2109-2117
61. Brar SS, Leon MB, Stone GW, et al. 2009. Use of drug-eluting stents in acute myocardial infarction. J. Am. Coll. Cardiol. 53:1677-1689
62. De Luca G, Stone GW, Suryapranata H, et al. 2009. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Int. J. Cardiol. 133:213-222
63. Kastrati A, Dibra A, Spaulding C, et al. 2007. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur. Heart J. 28:2706-2713 (Pubitemid 350139205)
64. Pasceri V, Patti G, Speciale G, et al. 2007. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am. Heart J. 153:749-754
65. Piscione F, Piccolo R, Cassese S, et al. 2009. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials. Catheterization Cardiovasc. Interv. 74:323-332
66. Patel MR, Pfisterer ME, Betriu A, et al. 2009. Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). Am. J. Cardiol. 103:181-186
67. Brodie BR, Stuckey T, Downey W, et al. 2008. Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. Catheter. Cardiovasc. Interv. 72:893-900
68. Campo G, Saia F, Percoco G, et al. 2009. Long-term outcome after drug eluting stenting in patients with ST-segment Elevation Myocardial Infarction: Data from the REAL Registry. Int. J. Cardiol. In press
69. Hannan EL, Racz M, Walford G, et al. 2008. Drug-eluting versus bare-metal stents in the treatment of patients with ST-elevation myocardial infarction. J. Am. Coll. Cardiol. Interv. 1:129-135
70. Fuster V, Badimon L, Badimon JJ, et al. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 326:310-318
71. Fuster V, Badimon L, Badimon JJ, et al. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 326:242-250
72. White HD, Chew DP. 2008. Acute myocardial infarction. Lancet 372:570-584
73. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. 2005. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366:921-929
74. Vagaonescu TD, Moreyra AE, Wilson AC, et al. for the Myocardial Infarction Data Acquistion System (MIDAS) Investigators. 2008. Drug eluting stents are associated wtih better survival and outcomes than bare metal stents after percutaneous coronary intervention for acute myocardial infarction patients: a statewide registry study. Presented at Transcatheter Cardiovascular Therapeutics, Washington, DC, Oct. 13. http://www.tctmd.com/show.aspx?id=72372
75. Mehta SR, Yusuf S, Peters RJ, et al. 2001. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527-533
76. Steinhubl SR, Berger PB, Mann JT, 3rd, et al. 2002. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420
77. Grines CL, Bonow RO, Casey DE, Jr, et al. 2007. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J. Am. Coll. Cardiol. 49:734-739
78. Smith SC, Jr, Feldman TE, Hirshfeld JW, Jr, et al. 2006. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention\summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). J. Am. Coll. Cardiol. 47:216-235
79. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. 2006. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48:2584-2591
80. Eisenstein EL, Anstrom KJ, Kong DF, et al. 2007. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159-168
81. Mauri L. 2008. Dual antiplatelet therapy trial design. Presented at Transcatheter Therapeutics, Washington, DC, Oct. 15
82. Wiviott SD, Braunwald E, McCabe CH, et al. 2007. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357:2001-2015 (Pubitemid 350106708)
83. Montalescot G, Wiviott SD, Braunwald E, et al. 2009. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723-731
84. Wiviott SD, Braunwald E, McCabe CH, et al. 2008. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371:1353-1363
85. James S, Akerblom A, Cannon CP, et al. 2009. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am. Heart J. 157:599-605
86. HaudeM,ErbelR,Issa H,etal. 1993. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am. Heart J. 126:15-22 (Pubitemid 23201569)
87. ColomboA,HallP,Nakamura S,et al. 1995. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91:1676-1688
88. Leon MB, Baim DS, Popma JJ, et al. 1998. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339:1665-1671
89. Svilaas T, Vlaar PJ, Van Der Horst IC, et al. 2008. Thrombus aspiration during primary percutaneous coronary intervention. N. Engl. J. Med. 358:557-567
90. IijimaR, ShinjiH,IkedaN,etal. 2006. Comparisonofcoronary arterial findingbyintravascular ultrasound in patients with "transient no-reflow" versus "reflow" during percutaneous coronary intervention in acute coronary syndrome. Am. J. Cardiol. 97:29-33
91. Mauri L, Silbaugh TS, Wolf RE, et al. 2008. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 118:1817-1827